Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$16.7B
28M shares
52-week range
$373.00 – $677.90
67% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
www.medpace.comNo one on the platform currently holds MEDP.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 504,668 | $242.3M |
| Bridgewater Associatesas of 2026-03-31 | 41,135 | $19.8M |
No one on the platform has traded MEDP yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.9B | +13.5% | $17.60 | $17.45–$17.71 | 32.9× | 9 |
| 2027 | $3.0B | +5.7% | $19.35 | $18.86–$19.76 | 29.9× | 9 |
| 2028 | $3.3B | +8.8% | $21.50 | $20.47–$22.64 | 26.9× | 9 |
| 2029 | $3.4B | +5.1% | $23.63 | $22.79–$24.81 | 24.5× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-22 | $3.98 | $4.25 | +6.8% |
| 2026-04-22 | $3.92 | $4.28 | +9.2% |
| 2026-02-09 | $4.19 | $4.67 | +11.5% |
| 2025-10-22 | $3.53 | $3.86 | +9.3% |
| 2025-07-21 | $2.98 | $3.10 | +4.0% |
| 2025-04-21 | $3.06 | $3.67 | +19.9% |
| 2025-02-10 | $2.96 | $3.67 | +24.0% |
| 2024-10-21 | $2.78 |
| $3.01 |
| +8.3% |
| $12.8B |
| — |
| ILMNIllumina, Inc. | $192.64 | -0.14% | $29.1B | — |
| SNNSmith & Nephew plc | $30.11 | +0.90% | $12.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$MEDP 16 billion just 1600 followers after bering a ten bagger over 10 years... find good trends with NO friends @STRelativeStrength
View on StockTwits ↗How To Find A Long Term Winner With Tenet Research $MEDP Watch this Video to learn How to Find Such Swing Trade Opportunities and repeatable swing setups. https://x.com/TENETTRADEGROUP/status/2081832118313980171?s=20
View on StockTwits ↗🚨 How to Grow Account with Long Term Swings -70% Gainer Learn > How to Find A+ Setup > Learn Daily Chart Analysis > Master GAP FILL Setups > Fundament Research with tenetresearch.ai > How to take Profits > $MEDP 70% Winner Recap > Biotech Trading https://x.com/i/status/2081120209578914037
View on StockTwits ↗Fundamental analysis of $MEDP (Medpace Holdings, Inc.) based on financial data and reported results. #MEDP #Medpace
View on StockTwits ↗$MEDP BMO raises target price to $600 from $400 Jefferies raises target price to $560 from $515 Leerink Partners raises target price to $620 from $515 Mizuho raises target price to $665 from $586 RBC raises target price to $692 from $484 TD Cowen raises target price to $492 from $419 Truist Securities raises target price to $609 from $462
View on StockTwits ↗$MEDP BMO raises target price to $600 from $400 Jefferies raises target price to $560 from $515 Leerink Partners raises target price to $620 from $515 Mizuho raises target price to $665 from $586 RBC raises target price to $692 from $484 TD Cowen raises target price to $492 from $419 Truist Securities raises target price to $609 from $462
View on StockTwits ↗$MEDP the chart is telling a stronger story than expected.
View on StockTwits ↗$MTEN about to skyrocket! Huge green candles soon! Last call! You’re all welcome! $MEDP $PAVS $ZCMD $NVVE
View on StockTwits ↗@No_Face_character @WAJeff @Jblack500 @BustaCapital @cynicaloptimist @IsabellaDC $MEDP +71.89
View on StockTwits ↗$MEDP Positive (78%): shares face upward price pressure because stronger-than-expected bookings can support higher revenue forecasts and reduce concern about future project demand; the reported 12.9% same-day gain shows that this repricing was already substantial. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/47824cbb407f22f5?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗$MEDP good results but trading at 38 xPE is expensive even at growth rate. It will settle around 475-525$ range. Ie 30x 2027 earnings still expensive.
View on StockTwits ↗$MEDP Medpace Holdings surged ~18% Wednesday after Medpace blew past Q2 estimates. Revenue +17.2% to $707.3M, EPS $4.25, and net new business awards up 28.2% to $795.7M. The bookings rebound is back. 📈 #MEDP #Medpace #CRO #Earnings https://prismmarketview.com/medpace-stock-gainsp-18-as-q2-earnings-and-bookings-crush-expectations/
View on StockTwits ↗$MEDP 🚨 Hit 671 from 386 Idea long that I gave on X tweets and in our portfolios at tenetresearch.ai After $CELC another Big winner for X followers and Tenet Group members!
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-22-medpace-holdings-inc-stock/ $MEDP Medpace Earnings Transcript
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.